We’re delighted to announce that a study carried out by Research Partnership on behalf of Janssen Pharmaceuticals into the association between Fibroblast growth factor receptor alteration (FGFRa) receptors and the clinical outcomes of patients with advanced or metastatic urothelial cancer (mUC) was selected by the American Society of Clinical Oncology for an e-poster presentation at the ASCO Annual Meeting in June 2021.
The poster, which is entitled, ‘Fibroblast growth factor receptor alteration (FGFRa) status and progression outcomes of patients with advanced or metastatic urothelial cancer (mUC)’ is authored
by Sarah Fleming of Janssen Pharmaceuticals in partnership with Phil Rosenberg and Chris Gaj of Research Partnership.
About the poster
FGFRa appear in approximately 15% of cases of mUC. Data on whether FGFRa in mUC have a prognostic impact or predictive benefit for particular treatments have been limited by small sample sizes. The objective of this study was to evaluate the association between tumor FGFRa and clinical outcomes of patients with advanced UC or mUC regardless of therapy type and status.
A sample of oncologists and urologists across the United States provided patient level data on 400 patients with stage IIIb or IV UC via a standardized questionnaire over a 1-month period (August 17, 2020 – September 20, 2020). The questionnaire included physician characteristics, patient demographic information, FGFR status, therapy given, response, and clinical and radiographic measures of progression.
A full abstract of the study is available to view online.
Research Partnership
All the latest news from Research Partnership
